825 Alameda Blvd, Coronado, CA 92118 • 858-735-5454
1535 Dale St, San Diego, CA 92102
Del Mar, CA
229 81St St, New York, NY 10028 • 212-737-8966
229 E 81St St #Q, New York, NY 10028 • 212-737-8966
Dix Hills, NY
Medford, NY
Work
Company:
La Jolla Office
Address:
10666 N Torrey Pines Rd, La Jolla, CA 92037
Phones:
800-727-4777 858-554-8065
Education
School / High School:
Tel Aviv University / Sackler Faculty of Medicine
Skills
Clinical Research • Clinical Trials • Clinical Development • Pharmaceutical Industry • Gcp • Drug Development • Medical Writing • Regulatory Submissions • Cro • Ctms • Translational Medicine • Pharmacovigilance • Medical Affairs • Therapeutic Areas • Oncology
Languages
English
Awards
Healthgrades Honor Roll
Ranks
Certificate:
Allergy & Immunology, 2005
Industries
Pharmaceuticals
Specialities
Internal Medicine • Allergy & Immunology
Us Patents
Method Of Treating Psoriatic Arthritis Patients With Inadequate Response To Tnf Therapy With Anti-Il23 Specific Antibody
- Horsham PA, US Chetan Karyekar - Horsham PA, US Alexa Kollmeier - San Diego CA, US Wim Noel - Flemish Brabant, BE Jaime Oliver Vigueras - Zug, CH Agata Schubert-Wlodarczyk - Warsaw, PL May Shawi - Horsham PA, US Virginia Taliadouros - Leiden, NL Elke Theander - Uppland, SE Xie Xu - San Diego CA, US
International Classification:
C07K 16/24 A61P 19/02 A61P 37/06
Abstract:
A method of treating psoriatic arthritis in a patient having showed an inadequate response to treatment with an anti-TNF therapy by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16, 24 and 48 weeks after initial treatment.
Safe And Effective Method Of Treating Psoriatic Arthritis With Anti-Il23 Specific Antibody
- Horsham PA, US Alexa Kollmeier - San Diego CA, US Xie Xu - San Marcos CA, US
International Classification:
C07K 16/24 A61P 19/02
Abstract:
A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant improvement in clinical endpoints, such as ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis, as measured 16 and 24 weeks after initial treatment.
Name / Title
Company / Classification
Phones & Addresses
Alexa Kollmeier Medical Doctor, Principal
Ofc of Alexa P Kollmeier MD Nonclassifiable Establishments
1535 Dl St, San Diego, CA 92102
Alexa Pilar Kollmeier
Alexa Kollmeier MD Allergist · Internist
10666 N Torrey Pne Rd, La Jolla, CA 92037 858-554-6158
Janssen, Pharmaceutical Companies of Johnson and Johnson since Dec 2008
Director Clinical Research
Allergy and Asthma Medical Group and Research Center since Jan 2004
Allergist/Immunologist
Profil Institute for Clinical Research, Inc. Jan 2004 - Nov 2008
Associate Medical Director
Education:
Sackler School of Medicine
MD
Tulane University, Newcomb College
BS
Skills:
Clinical Research Clinical Trials Clinical Development Pharmaceutical Industry Gcp Drug Development Medical Writing Regulatory Submissions Cro Ctms Translational Medicine Pharmacovigilance Medical Affairs Therapeutic Areas Oncology
Medicine Doctors
Dr. Alexa P Kollmeier, La Jolla CA - MD (Doctor of Medicine)
La Jolla Office 10666 N Torrey Pines Rd, La Jolla, CA 92037
Scripps Green Hospital 10666 North Torrey Pines Road, La Jolla, CA 92037
Scripps Memorial Hospital Encinitas 354 Santa Fe Drive, Encinitas, CA 92024
Education:
Medical School Tel Aviv University / Sackler Faculty of Medicine Medical School Montefiore Medical Center-Moses Division Medical School Scripps Green Hosp